{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T03:12:53Z","timestamp":1785553973789,"version":"3.56.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.clml.2023.03.014","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T03:51:32Z","timestamp":1680234692000},"page":"471-476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["SOHO State of the Art Updates and Next Questions |Treatment Approaches for Nodular Lymphocyte-Predominant Hodgkin Lymphoma"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2640-5255","authenticated-orcid":false,"given":"Michael S.","family":"Binkley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana H.","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.03.014_bib0001","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"issue":"7","key":"10.1016\/j.clml.2023.03.014_bib0002","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1200\/JCO.19.00986","article-title":"Long-term follow-up of patients with nodular lymphocyte-predominant Hodgkin lymphoma treated in the HD7 to HD15 trials: a report from the German Hodgkin Study Group","volume":"38","author":"Eichenauer","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.03.014_bib0003","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1182\/blood.2019003877","article-title":"Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG","volume":"135","author":"Binkley","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.03.014_bib0004","doi-asserted-by":"crossref","first-page":"e987","DOI":"10.1097\/MD.0000000000000987","article-title":"Prevalence of common non-Hodgkin lymphomas and subtypes of Hodgkin lymphoma by nodal site of involvement","volume":"94","author":"Laurent","year":"2015","journal-title":"Med (Baltimore)"},{"issue":"4","key":"10.1016\/j.clml.2023.03.014_bib0005","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM198801283180404","article-title":"Nodular and diffuse types of lymphocyte predominance Hodgkin's disease","volume":"318","author":"Regula","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.03.014_bib0006","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1200\/JCO.2014.60.4363","article-title":"Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group","volume":"33","author":"Eichenauer","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.03.014_bib0007","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1200\/JCO.2015.65.3469","article-title":"Minimal treatment of low-risk, pediatric lymphocyte-predominant Hodgkin lymphoma: a report from the children's oncology group","volume":"34","author":"Appel","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.03.014_bib0008","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood-2018-10-877761","article-title":"Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma","volume":"133","author":"Borchmann","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.03.014_bib0009","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.3390\/cancers13123021","article-title":"Pitfalls in the diagnosis of nodular lymphocyte predominant Hodgkin lymphoma: variant patterns, borderlines and mimics","volume":"13","author":"Younes","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2023.03.014_bib0010","doi-asserted-by":"crossref","first-page":"322","DOI":"10.6004\/jnccn.2022.0021","article-title":"NCCN Guidelines\u00ae Insights: Hodgkin lymphoma, version 2.2022","volume":"20","author":"Hoppe","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2023.03.014_bib0011","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1007\/s00259-014-2825-4","article-title":"Performance of FDG PET\/CT at initial diagnosis in a rare lymphoma: nodular lymphocyte-predominant Hodgkin lymphoma","volume":"41","author":"Grellier","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2023.03.014_bib0012","first-page":"753","article-title":"CD20-negative nodular lymphocyte-predominant Hodgkin lymphoma: a 20-Year consecutive case series from a tertiary cancer center","volume":"145","author":"Menke","year":"2020","journal-title":"Arch Pathol\u00a0Lab Med"},{"key":"10.1016\/j.clml.2023.03.014_bib0013","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1097\/00000478-200310000-00007","article-title":"Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation","volume":"27","author":"Fan","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clml.2023.03.014_bib0014","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/PAS.0000000000001005","article-title":"Bone marrow involvement in patients with nodular lymphocyte predominant Hodgkin lymphoma","volume":"42","author":"Agbay","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.clml.2023.03.014_bib0015","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.18376","article-title":"Tumour cell characteristics and microenvironment composition correspond to clinical presentation in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma","volume":"199","author":"Hartmann","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2023.03.014_bib0016","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3109\/10428194.2014.916802","article-title":"Bone marrow involvement in nodular lymphocyte predominant Hodgkin lymphoma occurs in tumors with a variant pattern","volume":"56","author":"Panjwani","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.03.014_bib0017","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/bjh.13540","article-title":"Childhood and Adolescent nodular lymphocyte predominant Hodgkin lymphoma - a review of clinical outcome based on the histological variants","volume":"171","author":"Shankar","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2023.03.014_bib0018","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1182\/blood-2013-07-515825","article-title":"The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)","volume":"122","author":"Hartmann","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.03.014_bib0019","unstructured":"Hartmann S, Soltani AS, Bankov K, et al. Tumor cell characteristics and microenvironment composition correspond to clinical presentation in newly diagnosed nodular lymphocyte predominant Hodgkin lymphoma."},{"key":"10.1016\/j.clml.2023.03.014_bib0020","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26753","article-title":"Variant histology, IgD and CD30 expression in low-risk pediatric nodular lymphocyte predominant Hodgkin lymphoma: a report from the Children's Oncology Group","volume":"65","author":"Untanu","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2023.03.014_bib0021","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3324\/haematol.2018.203224","article-title":"JUNB, DUSP2, SGK1, SOCS1 and CREBBP are frequently mutated in T-cell\/histiocyte-rich large B-cell lymphoma","volume":"104","author":"Schuhmacher","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2023.03.014_bib0022","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.03.014_bib0023","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3324\/haematol.2020.268813","article-title":"Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis: a standardized approach with underappreciated potential","volume":"107","author":"Raman","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2023.03.014_bib0024","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1084\/jem.20080809","article-title":"Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis","volume":"205","author":"Brune","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.clml.2023.03.014_bib0025","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.03.014_bib0026","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.03.014_bib0027","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1200\/JCO.2003.01.079","article-title":"Lymphocyte-predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection\u2013a study of the French Society of Pediatric Oncology","volume":"21","author":"Pellegrino","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.03.014_bib0028","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1055\/s-0035-1559664","article-title":"Pediatric nodular lymphocyte-predominant Hodgkin lymphoma: treatment recommendations of the GPOH-HD study group","volume":"227","author":"Mauz-K\u00f6rholz","year":"2015","journal-title":"Klin Padiatr"},{"key":"10.1016\/j.clml.2023.03.014_bib0029","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1182\/bloodadvances.2018029140","article-title":"Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma","volume":"3","author":"Pinnix","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.03.014_bib0030","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.2013.53.2069","article-title":"Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma","volume":"32","author":"Advani","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.03.014_bib0031","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1182\/bloodadvances.2021004375","article-title":"Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach","volume":"5","author":"Cheng","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.03.014_bib0032","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography\u2013guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.clml.2023.03.014_bib0033","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","article-title":"PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Borchmann","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2023.03.014_bib0034","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1182\/blood-2017-02-766121","article-title":"Encouraging activity for R-CHOP in advanced stage nodular lymphocyte\u2013predominant Hodgkin lymphoma","volume":"130","author":"Fanale","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.03.014_bib0035","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1200\/JCO.2009.26.3293","article-title":"What is the appropriate systemic chemotherapy for lymphocyte-predominant Hodgkin's lymphoma?","volume":"28","author":"Canellos","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.03.014_bib0036","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1182\/blood-2013-12-541078","article-title":"Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis","volume":"123","author":"Xing","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.03.014_bib0037","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.annonc.2021.02.018","article-title":"PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study","volume":"32","author":"Eichenauer","year":"2021","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.clml.2023.03.014_bib0038","first-page":"953","volume":"34","author":"Eichenauer","year":"2020","journal-title":"Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group. Leukemia"},{"key":"10.1016\/j.clml.2023.03.014_bib0039","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2009.24.9516","article-title":"Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma","volume":"28","author":"Al-Mansour","year":"2010","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.clml.2023.03.014_bib0040","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1182\/blood-2018-02-836437","article-title":"Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group","volume":"132","author":"Eichenauer","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.03.014_bib0041","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ajh.24927","article-title":"High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: a retrospective study by the European society for blood and marrow transplantation-lymphoma working party","volume":"93","author":"Akhtar","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2023.03.014_bib0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-021-00586-1","article-title":"Transformation and outcome of nodular lymphocyte predominant Hodgkin lymphoma: a finnish nationwide population-based study","volume":"11","author":"Kalashnikov","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2023.03.014_bib0043","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.24819","article-title":"Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the adult lymphoma study group","volume":"116","author":"Biasoli","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2023.03.014_bib0044","doi-asserted-by":"crossref","first-page":"E103","DOI":"10.1002\/ajh.23989","article-title":"Incidence, management, and outcome of high-grade transformation of nodular lymphocyte predominant Hodgkin lymphoma: long-term outcomes from a 30-year experience","volume":"90","author":"Eyre","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2023.03.014_bib0045","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1182\/blood-2015-08-665505","article-title":"Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution","volume":"127","author":"Kenderian","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.03.014_bib0046","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1182\/bloodadvances.2020002587","article-title":"CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy","volume":"4","author":"Thapa","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.03.014_bib0047","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1080\/0284186X.2018.1450522","article-title":"R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma","volume":"57","author":"Prusila","year":"2018","journal-title":"Acta Oncologica"},{"key":"10.1016\/j.clml.2023.03.014_bib0048","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2018-99-115836","article-title":"The tumor microenvironment of nodular lymphocyte predominant Hodgkin lymphoma is a unique immunobiological entity distinct from classical Hodgkin lymphoma","volume":"132","author":"Gunawardana","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.03.014_bib0049","doi-asserted-by":"crossref","first-page":"41","DOI":"10.18620\/ctt-1866-8836-2019-8-4-41-48","article-title":"Nivolumab in pediatric Hodgkin's lymphoma","volume":"8","author":"Kozlov","year":"2019","journal-title":"CTT"},{"issue":"16_suppl","key":"10.1016\/j.clml.2023.03.014_bib0050","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS3170","article-title":"Phase 1 study of KT-413, a targeted protein degrader, in adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma","volume":"40","author":"Stevens","year":"2022","journal-title":"JCO"},{"issue":"8","key":"10.1016\/j.clml.2023.03.014_bib0051","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1080\/10428194.2022.2053533","article-title":"Practice patterns for the management of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): an international survey by the Global NLPHL One Working Group (GLOW)","volume":"63","author":"Lo","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.03.014_bib0052","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/bjh.18406","article-title":"Characterizing the immune microenvironment for nodular lymphocyte-predominant Hodgkin lymphoma","volume":"199","author":"Binkley","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2023.03.014_bib0053","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2013.52.5410","article-title":"Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the children's oncology group study AHOD0031","volume":"32","author":"Friedman","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.03.014_bib0054","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023001118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023001118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:42:08Z","timestamp":1761871328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023001118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":54,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S2152265023001118"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.03.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions |Treatment Approaches for Nodular Lymphocyte-Predominant Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}